Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients.
Assays based on the molecular detection of genetic changes in serum have been shown as potential diagnostic tools for colorectal cancer. We examined the methylation status of p16 in colorectal cancers using methylation-specific PCR (MSP). Forty-four of 94 (47%) cancer DNA exhibited abnormal promoter methylation of p16 gene while no corresponding normal DNA exhibited such methylation. Subsequently, we examined whether aberrant methylation could be detected in corresponding serum DNA, and found that 13 of 44 (30%) patients with p16 promoter methylation in tumor DNA demonstrated abnormal methylation in their serum DNA. Moreover, abnormal methylation was found in the serum of patients in all clinical stages, suggesting that early colorectal cancer could be detected using the MSP method.
Nakayama
Hiroshi
H
Second Department of Surgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Japan.
Hibi
Kenji
K
Taguchi
Masumi
M
Takase
Tsunenobu
T
Yamazaki
Taiji
T
Kasai
Yasushi
Y
Ito
Katsuki
K
Akiyama
Seiji
S
Nakao
Akimasa
A
D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics
D019941:Cyclin-Dependent Kinase Inhibitor p16; D004273:DNA, Neoplasm